156 related articles for article (PubMed ID: 21224742)
1. Willingness to pay per quality-adjusted life year: is one threshold enough for decision-making?: results from a study in patients with chronic prostatitis.
Zhao FL; Yue M; Yang H; Wang T; Wu JH; Li SC
Med Care; 2011 Mar; 49(3):267-72. PubMed ID: 21224742
[TBL] [Abstract][Full Text] [Related]
2. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?
Shiroiwa T; Sung YK; Fukuda T; Lang HC; Bae SC; Tsutani K
Health Econ; 2010 Apr; 19(4):422-37. PubMed ID: 19382128
[TBL] [Abstract][Full Text] [Related]
3. Willingness to pay per quality-adjusted life year in a study of knee osteoarthritis.
Byrne MM; O'malley K; Suarez-Almazor ME
Med Decis Making; 2005; 25(6):655-66. PubMed ID: 16282216
[TBL] [Abstract][Full Text] [Related]
4. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation.
King JT; Tsevat J; Lave JR; Roberts MS
Med Decis Making; 2005; 25(6):667-77. PubMed ID: 16282217
[TBL] [Abstract][Full Text] [Related]
5. Willingness to pay for a QALY.
Gyrd-Hansen D
Health Econ; 2003 Dec; 12(12):1049-60. PubMed ID: 14673813
[TBL] [Abstract][Full Text] [Related]
6. Quality-adjusted life years was a poor predictor of women's willingness to pay in acute and chronic conditions: results of a survey.
Franic DM; Pathak DS; Gafni A
J Clin Epidemiol; 2005 Mar; 58(3):291-303. PubMed ID: 15718119
[TBL] [Abstract][Full Text] [Related]
7. A welfare economic approach to measure outcomes in stuttering: comparing willingness to pay and quality adjusted life years.
Franic DM; Bothe AK; Bramlett RE
J Fluency Disord; 2012 Dec; 37(4):300-13. PubMed ID: 23218213
[TBL] [Abstract][Full Text] [Related]
8. Does willingness to pay per quality-adjusted life year bring us closer to a useful decision rule for cost-effectiveness analysis?
Polsky D
Med Decis Making; 2005; 25(6):605-6. PubMed ID: 16282209
[No Abstract] [Full Text] [Related]
9. A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold?
Nimdet K; Chaiyakunapruk N; Vichansavakul K; Ngorsuraches S
PLoS One; 2015; 10(4):e0122760. PubMed ID: 25855971
[TBL] [Abstract][Full Text] [Related]
10. Relationship between quality of life instruments, health state utilities, and willingness to pay in patients with asthma.
Blumenschein K; Johannesson M
Ann Allergy Asthma Immunol; 1998 Feb; 80(2):189-94. PubMed ID: 9494453
[TBL] [Abstract][Full Text] [Related]
11. Disentangling WTP per QALY data: different analytical approaches, different answers.
Gyrd-Hansen D; Kjaer T
Health Econ; 2012 Mar; 21(3):222-37. PubMed ID: 21254305
[TBL] [Abstract][Full Text] [Related]
12. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
13. Determination of Cost-Effectiveness Threshold for Health Care Interventions in Malaysia.
Lim YW; Shafie AA; Chua GN; Ahmad Hassali MA
Value Health; 2017 Sep; 20(8):1131-1138. PubMed ID: 28964445
[TBL] [Abstract][Full Text] [Related]
14. Willingness-to-pay stated preferences for 8 health-related quality-of-life domains in psoriatic arthritis: a pilot study.
Hu SW; Holt EW; Husni ME; Qureshi AA
Semin Arthritis Rheum; 2010 Apr; 39(5):384-97. PubMed ID: 19095293
[TBL] [Abstract][Full Text] [Related]
15. Comorbidities, quality of life and patients' willingness to pay for a cure for type 2 diabetes in Taiwan.
Chang K
Public Health; 2010 May; 124(5):284-94. PubMed ID: 20546817
[TBL] [Abstract][Full Text] [Related]
16. Can we estimate the 'social' value of a QALY? Four core issues to resolve.
Smith RD; Richardson J
Health Policy; 2005 Sep; 74(1):77-84. PubMed ID: 16098414
[TBL] [Abstract][Full Text] [Related]
17. [Economic examination of the 2006/7 update of the Israeli national list of health services].
Shmueli A; Nissan-Englcin E
Harefuah; 2008 Jun; 147(6):488-92, 576. PubMed ID: 18693622
[TBL] [Abstract][Full Text] [Related]
18. GET MORE, PAY MORE? An elaborate test of construct validity of willingness to pay per QALY estimates obtained through contingent valuation.
Bobinac A; van Exel NJ; Rutten FF; Brouwer WB
J Health Econ; 2012 Jan; 31(1):158-68. PubMed ID: 22018622
[TBL] [Abstract][Full Text] [Related]
19. Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura.
Xie F; Blackhouse G; Assasi N; Campbell K; Levin M; Bowen J; Tarride JE; Pi D; Goeree R
Clin Ther; 2009 May; 31(5):1082-91; discussion 1066-8. PubMed ID: 19539109
[TBL] [Abstract][Full Text] [Related]
20. A utility-theoretic model for QALYs and willingness to pay.
Klose T
Health Econ; 2003 Jan; 12(1):17-31. PubMed ID: 12483758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
